Frontotemporal Degeneration News and Research

RSS

UTHSC researchers secure $308,000 grant from Department of Defense for dementia study

Repeated traumatic brain injuries (TBI) in soldiers and military personnel can cause behavioral, neurological, and cognitive effects and lead to dementia.

19 Feb 2023

USC researchers identify two promising avenues for developing new ALS treatments

Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years.

7 Feb 2023

17 recommendations for better communication with study participants affected by early stopping of clinical trials

Participants in clinical trials can feel abandoned and adrift when their studies end early and they are the last to be informed, or they hear about it first from news or social media.

2 Aug 2022

Cell-hobbling fibrils found across diverse neurodegenerative diseases

Take a cell-deep tour of a brain afflicted with Alzheimer's disease, and you will find minuscule clumps of protein that seem suspicious. Ever since the 1980s, when neuroscientists began identifying these protein tangles, researchers have discovered that other brain diseases have their own tangled-protein signatures.

4 Mar 2022

Mount Sinai researchers use cerebral organoids to study frontotemporal dementia

Frontotemporal dementias are a group of fatal and debilitating brain disorders for which there are no cures.

26 Jul 2021

ATN framework can be extended to detect frontotemporal degeneration

Alzheimer's disease and related diseases can still only be confirmed in deceased patients' brains via autopsy.

20 Jul 2021

Research identifies distinctive inflammatory signature in a genetic form of ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that strikes nearly 5,000 people in the U.S. every year. About 10% of ALS cases are inherited or familial, often caused by an error in the C9orf72 gene.

16 Jun 2021

Expert panel provides guidance for optimized design of early drug trials for Alzheimer's, related dementias

An expert panel convened by the Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) provides guidance on best practices for the design of early drug trials for Alzheimer's disease, frontotemporal degeneration (FTD), and other neurodegenerative dementias.

19 May 2021

NeuroVision Imaging receives ADDF funding to develop biomarker tests for Alzheimer's disease

NeuroVision Imaging Inc., announced today it has received an investment from the Alzheimer's Drug Discovery Foundation to support developing reliable, affordable biomarker tests for Alzheimer's disease and other forms of dementia and neurodegenerative disorders.

3 Feb 2021

Nearly $4 million to fund drug discovery research for Alzheimer's, other dementia

The Alzheimer's Association and the Rainwater Charitable Foundation have joined forces again to fund drug discovery research towards finding therapies for Alzheimer's disease, frontotemporal degeneration, and other tauopathies.

4 Mar 2020

ADDF announces new awards through its Diagnostics Accelerator initiative

The Alzheimer's Drug Discovery Foundation announced six new investments totaling $6 million through its Diagnostics Accelerator initiative.

4 Dec 2019

Penn researchers to develop critical tool for imaging the brains of patients with Parkinson's

Researchers in the Perelman School of Medicine at the University of Pennsylvania will lead a multi-institutional effort in pursuit of developing a critical tool for imaging the brains of patients with Parkinson's and other neurodegenerative diseases.

10 Oct 2019

ADDF’s new initiative aims to advance digital tools for Alzheimer's and dementias

As part of its Diagnostics Accelerator research program, the Alzheimer's Drug Discovery Foundation announced today a new initiative that aims to fast-track the development of digital tools for Alzheimer's disease and related dementias.

4 Apr 2019

PARP inhibitors show promise for treating and preventing brain disorders

A class of cancer drugs called PARP inhibitors could be useful for treating and preventing brain disorders, including amyotrophic lateral sclerosis, also called Lou Gehrig's disease, and some forms of frontotemporal degeneration, by halting the misplacement of specific proteins that affect nerve cells, according to a study published in Molecular Cell by researchers in the the School of Arts and Sciences and the Perelman School of Medicine at the University of Pennsylvania.

10 Aug 2018

Learning to live well with dementia

Imagine your doctor telling you have Alzheimer's disease or some other type of dementia. Then, imagine being told, "I'm sorry, there's nothing we can do. You might want to start getting your affairs in order."

9 Aug 2018

Study captures economic burden of frontotemporal degeneration in the United States

You may not have heard of it, but frontotemporal degeneration (FTD) accounts for 20 to 50 percent of dementia cases in people under the age of 65. FTD ravages an individual's quality of life by dramatically altering their language, personality, behavior, cognition and motor function. But it doesn't end there.

4 Oct 2017

A rare dementia gene runs in the family, but he’s fine — so far

John Janda knows he takes after his mother. At 68, the graying building contractor is sentimental, just as she was. He smiles indulgently as he shows off photos of his 9-month-old grandson; he tears up at the memory of losing his dad in a construction accident more than 40 years ago.

11 Sep 2017

Retinal imaging may help doctors confirm or rule out frontotemporal degeneration

Frontotemporal degeneration (FTD) is a progressive neurodegenerative condition that is present in tens of thousands of Americans, but is often difficult to diagnose accurately.

8 Sep 2017

Penn study finds evidence of AD neuropathology in post-mortem brains of LBD patients

Patients who had a diagnosis of Parkinson's disease (PD) with dementia (PDD) or dementia with Lewy bodies (DLB) and had higher levels of Alzheimer's disease (AD) pathology in their donated post-mortem brains also had more severe symptoms of these Lewy body diseases (LBD) during their lives, compared to those whose brains had less AD pathology, according to research from the Perelman School of Medicine at the University of Pennsylvania.

6 Jan 2017

Genetic mutation linked to ALS, FTD prevents proteins from entering and exiting the cell's nucleus

Three teams of scientists supported by the National Institutes of Health showed that a genetic mutation linked to some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) may destroy neurons by disrupting the movement of materials in and out of the cell's nucleus, or command center where most of its DNA is stored.

19 Oct 2015